Factors such as patient preferences, frequency of dosing, comorbidities, and the primary goals of treatment whether focused on glycemic control, weight loss, or a combination of both play pivotal roles in guiding healthcare professionals and patients towards the most suitable therapeutic option
Your provider supports you through every step
However, only semaglutide (under the brand Wegovy) is currently FDA-approved for weight loss in non-diabetic individuals
Our providers focus on: Safe and effective dosing plans Ongoing progress monitoring Personalized treatment strategies Holistic wellness support We help patients not just lose weight but transform their overall health and confidence
Mounjaro, like other glucagon-like peptide-1 (GLP-1) receptor agonists, can cause sulfur burps in some users
Always compare in milligrams, never in units